Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

VKTX

+ Watchlist+ Portfolio

Viking Therapeutics, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$26.88
52-Week Range
$23.82 – $43.10
Market Cap
$3.34B
P/E (TTM)
—
EPS (TTM)
-5.42
Dividend Yield
0.00%
Advanced Metrics
Price/Book
5.67
PEG Ratio
—
Return on Equity
-96.37%
Return on Assets
-47.23%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
7.27
Debt/Equity
0.43
Total Debt
$254.69M
Free Cash Flow
$-237.78M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$2.63B

Market Snapshot

About

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. The company's pipeline includes drug candidates for non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, and other metabolic conditions. Viking focuses on small molecule therapeutics targeting nuclear receptors.